TORONTO, Nov 21 (Reuters) - Labopharm Inc (DDS.TO: Quote, Profile, Research) said on Wednesday the U.S. Food and Drug Administration responded to its appeal of the approvable letter for its once-daily tramadol, and that the agency will not overturn the letter, which was issued in May.
